Still no suppression on 5mg Mounjaro — what's actually happening

Why 5mg often isn't where the appetite change shows up

Mounjaro's licensed schedule asks patients to stay at each dose for roughly four weeks before moving up. That pacing exists because the gastrointestinal side effects (nausea, bloating, discomfort) tend to be sharpest when the dose rises, and slowing the increases gives the body time to settle. The clinical consequence is that the lower doses, including 5mg, function as adjustment steps rather than the dose a prescriber is aiming to reach.

The NHS tirzepatide medicines page describes this stepped approach plainly: treatment begins at 2.5mg and progresses, with the prescriber directing timing. The headline weight-loss results from the SURMOUNT-1 trial (roughly 20% average body-weight reduction over 72 weeks) were achieved at the 15mg maintenance dose, not at the earlier steps. Comparing your 5mg experience with those numbers is, in a word, premature.

That said, some people do feel a clear reduction in hunger at 5mg. Biology varies. If you have noticed nothing at all after a full four weeks, that is worth raising with your prescriber rather than assuming the medicine has failed. The appetite signal can also be subtle at first (a smaller portion feeling adequate, a meal skipped without noticing) so it helps to track your experience rather than wait for a dramatic shift that may not come.

What else can suppress or obscure the effect at this dose

Sleep deprivation raises ghrelin, the hormone most directly responsible for hunger. A run of poor nights can drown out whatever appetite-reducing signal 5mg is generating. The same applies to chronic stress, which pushes cortisol up and hunger with it. These are not reasons to discount the medicine, they are reasons the clinical picture is more complex than a single dose number.

Injection technique and storage both matter more than people realise. Tirzepatide should be refrigerated at 2–8°C; a pen that has been left somewhere warm (a bathroom cabinet, a car glove box over a hot week) may have degraded without any visible sign. If you collect your pen just before a bank holiday, check storage conditions carefully for that extended period. Site rotation (abdomen, thigh, upper arm) and the angle and pace of injection can also affect absorption, and our prescribers hear about technique issues regularly, it is not an embarrassing question to raise.

If you are on the 5mg dose and nothing has shifted after four full weeks, the honest assessment is: raise it with your prescriber before the next step, not after. You can also read more about how earlier-dose experiences compare on the 2.5mg suppression page, since the pattern is similar and the explanations largely overlap.

When the clinical decision is to move up, and when it is not

A prescriber reviewing your case at the 5mg stage will be weighing several things: any side effects you have experienced, how your weight has changed (if at all), and your own account of appetite change. The absence of suppression at 5mg is not, by itself, a reason to rush up or to stop. NICE's appraisal of tirzepatide (TA1026) notes that treatment should be reviewed if less than 5% weight loss has occurred after six months at the highest tolerated dose, the standard is set at the highest tolerated dose, which most people have not yet reached at 5mg.

In some cases, a prescriber will advise staying at 5mg for a second four-week period if side effects were significant during the first, to avoid stacking an increase on top of a system still adjusting. In others, moving to 7.5mg is appropriate. That call belongs with the clinician, not with a forum post or a drug-comparison chart.

For context on what the full dose ladder looks like, the 5mg treatment overview and the broader Mounjaro information page both walk through the schedule factually, including details on how treatment is structured from the very first 0.25mg step. Questions about what a clinical review involves and how the process works are answered on the FAQs page.

How to have a useful conversation with your prescriber about this

The most practical thing you can do before your next review is keep a short daily note: hunger level morning and evening, any change in portion size, sleep quality, stress, anything unusual about injection day. A week of that data is far more useful than a general impression. Your prescriber cannot assess what they cannot see.

Be specific about injection practice too, which site, roughly what time of day, whether the pen was at room temperature before use. The Mounjaro SmPC on the eMC (electronic Medicines Compendium) sets out the storage and administration guidance in full; it is worth a read before the conversation.

If you started with a different provider and are transferring care, or if you feel the current review process is not giving you enough time to discuss dose progress, that is a reasonable thing to raise. At nume, a real prescriber reviews every patient's situation before any repeat or dose change, not a set of automated prompts. Pricing for treatment is outlined on the Mounjaro cost page, and if you want to discuss your current progress with our clinical team, you can speak to our prescribers here.